156 related articles for article (PubMed ID: 9365092)
21. Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with corticosteroid treatment.
Pirro M; Bocci EB; Di Filippo F; Schillaci G; Mannarino MR; Bagaglia F; Gerli R; Mannarino E
J Intern Med; 2012 Aug; 272(2):177-84. PubMed ID: 22211720
[TBL] [Abstract][Full Text] [Related]
22. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
23. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone.
Verhoeven AC; Boers M; te Koppele JM; van der Laan WH; Markusse HM; Geusens P; van der Linden S
Rheumatology (Oxford); 2001 Nov; 40(11):1231-7. PubMed ID: 11709606
[TBL] [Abstract][Full Text] [Related]
24. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis.
Lundberg I; Hedfors E
J Rheumatol; 1990 Oct; 17(10):1340-5. PubMed ID: 2254893
[TBL] [Abstract][Full Text] [Related]
25. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study.
Salvarani C; Cantini F; Niccoli L; Macchioni P; Consonni D; Bajocchi G; Vinceti M; Catanoso MG; Pulsatelli L; Meliconi R; Boiardi L
Arthritis Rheum; 2005 Feb; 53(1):33-8. PubMed ID: 15696567
[TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica.
Kimura M; Tokuda Y; Oshiawa H; Yoshida K; Utsunomiya M; Kobayashi T; Deshpande GA; Matsui K; Kishimoto M
J Rheumatol; 2012 Jan; 39(1):148-53. PubMed ID: 22174210
[TBL] [Abstract][Full Text] [Related]
27. In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers.
Straub RH; Georgi J; Helmke K; Vaith P; Lang B
Rheumatology (Oxford); 2002 Apr; 41(4):423-9. PubMed ID: 11961173
[TBL] [Abstract][Full Text] [Related]
28. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.
Gonzalez-Gay MA; Garcia-Porrua C; Miranda-Filloy JA; Martin J
Drugs Aging; 2006; 23(8):627-49. PubMed ID: 16964987
[TBL] [Abstract][Full Text] [Related]
29. Corticosteroid requirements in polymyalgia rheumatica.
Weyand CM; Fulbright JW; Evans JM; Hunder GG; Goronzy JJ
Arch Intern Med; 1999 Mar; 159(6):577-84. PubMed ID: 10090114
[TBL] [Abstract][Full Text] [Related]
30. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal.
Corrigall VM; Dolan AL; Dasgupta B; Panayi GS
Br J Rheumatol; 1997 Sep; 36(9):976-80. PubMed ID: 9376994
[TBL] [Abstract][Full Text] [Related]
31. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
32. Bone mineral density in patients with temporal arteritis and polymyalgia rheumatica.
Mateo L; Nolla JM; Rozadilla A; Rodríguez-Moreno J; Niubó R; Valverde J; Roig-Escofet D
J Rheumatol; 1993 Aug; 20(8):1369-73. PubMed ID: 8230021
[TBL] [Abstract][Full Text] [Related]
33. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.
Catanoso MG; Macchioni P; Boiardi L; Pipitone N; Salvarani C
Arthritis Rheum; 2007 Dec; 57(8):1514-9. PubMed ID: 18050171
[TBL] [Abstract][Full Text] [Related]
34. Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica.
Salvarani C; Boiardi L; Timms JM; Silvestri T; Ranzi A; Macchioni PL; Pulsatelli L; di Giovine FS
Clin Exp Rheumatol; 2000; 18(5):591-5. PubMed ID: 11072599
[TBL] [Abstract][Full Text] [Related]
35. Changes in bone mass and bone turnover following ankle fracture.
Ingle BM; Hay SM; Bottjer HM; Eastell R
Osteoporos Int; 1999; 10(5):408-15. PubMed ID: 10591839
[TBL] [Abstract][Full Text] [Related]
36. Insulin sensitivity and related cytokines, chemokines, and adipokines in polymyalgia rheumatica.
Kreiner F; Galbo H
Scand J Rheumatol; 2010; 39(5):402-8. PubMed ID: 20615159
[TBL] [Abstract][Full Text] [Related]
37. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment.
Kreiner FF; Borup R; Nielsen FC; Schjerling P; Galbo H
BMC Musculoskelet Disord; 2017 Aug; 18(1):341. PubMed ID: 28784116
[TBL] [Abstract][Full Text] [Related]
39. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica.
Kreiner F; Langberg H; Galbo H
Arthritis Rheum; 2010 Dec; 62(12):3768-75. PubMed ID: 20812339
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in polymyalgia rheumatica.
Matteson EL; Maradit-Kremers H; Cimmino MA; Schmidt WA; Schirmer M; Salvarani C; Bachta A; Dejaco C; Duftner C; Slott Jensen H; Poór G; Kaposi NP; Mandl P; Balint PV; Schmidt Z; Iagnocco A; Cantini F; Nannini C; Macchioni P; Pipitone N; Del Amo M; Espígol-Frigolé G; Cid MC; Martínez-Taboada VM; Nordborg E; Direskeneli H; Aydin SZ; Ahmed K; Hazelman B; Pease C; Wakefield RJ; Luqmani R; Abril A; Marcus R; Gonter NJ; Maz M; Crowson CS; Dasgupta B
J Rheumatol; 2012 Apr; 39(4):795-803. PubMed ID: 22422492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
